Contact
LinkedIn
Insights

Notes on the science we back.

New investments, exits, and our thoughts on where the science is going.

AllNewsInsights
A New Recessive Neurodevelopmental Disorder Hidden in the Noncoding Genome
Insights
·
April 9, 2026

A New Recessive Neurodevelopmental Disorder Hidden in the Noncoding Genome

Tachyon MP Ernest Turro and his team at Mount Sinai identify the most prevalent known recessive neurodevelopmental disorder, caused by variants in the noncoding gene RNU2-2

Read →
a-new-recessive-neurodevelopmental-disorder-hidden-in-the-noncoding-genome-rnu2
Biotech x AI: What Would an AI-Native Future Actually Look Like?
Insights
·
October 13, 2025

Biotech x AI: What Would an AI-Native Future Actually Look Like?

Biotech won’t go AI-native by adding an LLM. We outline closed-loop design→make/measure→learn systems, data moats, and what this means for founders and VCs.

Read →
ai-native-biotech-feedback-loops
Encoding a New Era in Gene Therapy: Why We Invested in Stylus Medicine
News
·
May 15, 2025

Encoding a New Era in Gene Therapy: Why We Invested in Stylus Medicine

Stylus combines precise gene insertion, large-payload delivery, and a clean, non-viral format to address both the biological and logistical challenges of scaling CAR T therapies.

Read →
gene-therapy-invested-stylus-medicine
AI Meets Biology: Redefining Therapeutic Discovery with AI Proteins
News
·
January 18, 2025

AI Meets Biology: Redefining Therapeutic Discovery with AI Proteins

AI Proteins combines advanced prediction algorithms in molecular biology with a complete preclinical development stack to create and validate novel miniproteins

Read →
ai-meets-biology-redefining-therapeutic-discovery-with-ai-proteins
Advancing RNA Therapeutics with miRecule
News
·
October 8, 2024

Advancing RNA Therapeutics with miRecule

miRecule's mission is to create RNA therapies that not only treat symptoms but also target the underlying genomic causes of disease, offering the potential for long-term remission.

Read →
advancing-rna-therapeutics-with-mirecule
Rescuing Uncontrolled Bleeding with Haima Therapeutics
News
·
June 24, 2024

Rescuing Uncontrolled Bleeding with Haima Therapeutics

Haima's platelet-inspired synthetic cell therapy mimics some of the mechanisms that platelets use to mitigate uncontrolled bleeding.

Read →
rescuing-uncontrolled-bleeding-with-haima-therapeutics
Embracing Novel Frontiers: Tachyon Ventures' First Investment in Palm Therapeutics
News
·
January 25, 2024

Embracing Novel Frontiers: Tachyon Ventures' First Investment in Palm Therapeutics

Palm Therapeutics is exploring a new mechanism called depalmitoylation as a method of deactivating harmful proteins.

Read →
embracing-novel-frontiers-tachyon-ventures-first-investment-in-palm-therapeutics
DTx Pharma: Revolutionizing RNA Medicine Delivery - From Series A Investment to Novartis Acquisition
News
·
July 25, 2023

DTx Pharma: Revolutionizing RNA Medicine Delivery - From Series A Investment to Novartis Acquisition

In May 2019, Tachyon Ventures embarked on an exciting journey by investing in DTx Pharma, a preclinical RNA startup based in San Diego.

Read →
dtx-pharma-revolutionizing-rna-medicine-delivery-from-series-a-investment-to-novartis-acquisition
Uncovering the Genetic Causes of Unexplained Rare Diseases
Insights
·
April 13, 2023

Uncovering the Genetic Causes of Unexplained Rare Diseases

Tachyon’s Co-Founder and Chief Scientific Officer, Ernest Turro, PhD, also Associate Professor at Mount Sinai in New York, has just published a major paper in Nature Medicine identifying the genetic causes of previously unexplained rare diseases through a unique computational approach developed by his team at Mount Sinai.

Read →
uncovering-the-genetic-causes-of-unexplained-rare-diseases
Accelerating peptide therapeutics with Peptilogics
News
·
March 7, 2023

Accelerating peptide therapeutics with Peptilogics

Our repeated investments into Peptilogics reflects our belief that a new era is underway for synthetic peptide drugs, supported by streamlined processes and AI-driven rational design that streamline the many moving parts of peptide drug development.

Read →
accelerating-peptide-therapeutics-with-peptilogics
Treating the root pathologies of neurological disorders with Axonis
News
·
July 27, 2022

Treating the root pathologies of neurological disorders with Axonis

Central nervous system (CNS) disorders are a broad category of neurological diseases, many of which have few or no therapeutic treatment options. Axonis, our most recent investment, has a novel approach for developing neuro-restorative, neuro-protective, and neuro-regenerative therapies.

Read →
therapies-treat-neurological-disorders-axonis
Targeting Disease-Causing Transcription Factors with Altay Therapeutics
Insights
·
May 23, 2022

Targeting Disease-Causing Transcription Factors with Altay Therapeutics

At Tachyon, we search for companies with the potential to address long established problems in biomedical science. One such challenge is the direct targeting of a class of proteins, known as transcription factors, using small molecules.

Read →
targeting-disease-causing-transcription-factors-with-altay-therapeutics
Advancing Gene Therapy with Chameleon Biosciences
Insights
·
February 21, 2022

Advancing Gene Therapy with Chameleon Biosciences

We’re excited to share our thoughts on how we believe Chameleon’s platform can overcome several obstacles faced by other companies in the field of AAV gene therapy, , and why we decided to invest in their recent Seed Round.

Read →
advancing-gene-therapy-chameleon-biosciences
Six key disruptors transforming biosciences into bioengineering
Insights
·
January 10, 2022

Six key disruptors transforming biosciences into bioengineering

Over the past 10 years, a set of key scientific innovations have transformed the way we understand and interact with human biology. From CRISPR gene editing to AI-powered drug discovery, these innovations are allowing scientists and entrepreneurs to shift their focus from exploration and discovery to the realm of biological design and creation.

Read →
six-key-disruptors-transforming-biosciences-into-bioengineering-tachyon-vc
Get in touch

Working on something in this space?

We'd rather see it early than polished.

Talk to usRead the thesis